Hypernil: Advanced Blood Pressure Control for Lasting Cardiovascular Health
Hypernil
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 60 | $1.13 | $68.00 (0%) | 🛒 Add to cart |
| 90 | $0.96 | $102.00 $86.00 (16%) | 🛒 Add to cart |
| 120 | $0.87 | $136.00 $104.00 (24%) | 🛒 Add to cart |
| 180 | $0.78 | $204.00 $140.00 (31%) | 🛒 Add to cart |
| 270 | $0.72 | $306.00 $194.00 (37%) | 🛒 Add to cart |
| 360 | $0.69
Best per tab | $408.00 $248.00 (39%) | 🛒 Add to cart |
Hypernil represents a significant advancement in the pharmacological management of hypertension, offering a targeted approach to blood pressure regulation. This prescription medication, containing the active ingredient Amlodipine Besylate, is a calcium channel blocker designed for precision in vascular smooth muscle relaxation. It is indicated for the treatment of hypertension in adults, either as monotherapy or in combination with other antihypertensive agents, and for the management of chronic stable angina and vasospastic angina. Developed through rigorous clinical research, Hypernil provides a reliable option for clinicians seeking to establish consistent hemodynamic stability in their patients, reducing the long-term risks associated with uncontrolled high blood pressure.
Features
- Active Ingredient: Amlodipine Besylate (5 mg or 10 mg per tablet)
- Pharmacological Class: Dihydropyridine Calcium Channel Blocker (CCB)
- Mechanism of Action: Selective inhibition of calcium ion influx across cardiac and vascular smooth muscle cell membranes
- Formulation: Film-coated, immediate-release oral tablets
- Bioavailability: Approximately 64-90% following oral administration
- Time to Peak Plasma Concentration: 6-12 hours post-dose
- Elimination Half-Life: 30-50 hours
- Protein Binding: Approximately 93%
- Metabolism: Extensive hepatic metabolism via CYP3A4 isoenzyme
- Excretion: Primarily renal (60%) with 20-25% fecal excretion
- Prescription Status: Rx-only medication requiring physician authorization
Benefits
- Achieves significant and sustained reduction in both systolic and diastolic blood pressure measurements
- Decreases myocardial oxygen demand through reduction of peripheral vascular resistance and afterload
- Demonstrates a favorable safety profile with a low incidence of metabolic disturbances
- Provides 24-hour blood pressure control with once-daily dosing, supporting medication adherence
- Shows efficacy across diverse patient populations, including elderly patients and those with diabetes
- Reduces the frequency of angina attacks and decreases nitrate consumption in patients with coronary artery disease
Common use
Hypernil is primarily prescribed for the management of essential hypertension. It is frequently utilized as first-line therapy or as part of combination treatment regimens when monotherapy proves insufficient. The medication finds particular utility in patients who may not tolerate beta-blockers or angiotensin-converting enzyme inhibitors due to contraindications or adverse effects. Clinical practice commonly employs Hypernil in patients with isolated systolic hypertension, a condition prevalent among elderly populations. Additionally, it serves as an effective antianginal agent for patients with chronic stable angina who require both blood pressure control and coronary symptom management. The medication has demonstrated consistent efficacy across various demographic groups, including post-menopausal women and patients with comorbid metabolic syndrome.
Dosage and direction
The recommended initial dosage for hypertension treatment is 5 mg orally once daily. This dosage may be increased to a maximum of 10 mg daily based on individual patient response and tolerance. For angina management, the starting dose is typically 5-10 mg once daily, with most patients responding at the lower end of this range. Dosage adjustments should occur at 7-14 day intervals to allow for full therapeutic effect development. Administration may occur with or without food, though consistency in timing relative to meals is recommended to maintain stable pharmacokinetics. Tablets should be swallowed whole with a full glass of water and not crushed or chewed. In elderly patients or those with hepatic impairment, initiation at 2.5 mg daily is advised with careful titration. The medication achieves steady-state plasma concentrations after 7-8 days of consistent dosing.
Precautions
Patients should undergo regular blood pressure monitoring, particularly during dosage adjustments. Hepatic function assessment is recommended before initiation and periodically during treatment, as amlodipine is extensively metabolized in the liver. Caution is advised in patients with severe aortic stenosis due to potential reduction in coronary perfusion. Peripheral edema, a known class effect of calcium channel blockers, may occur and typically presents as mild to moderate ankle swelling. Patients should be advised to avoid sudden position changes due to potential orthostatic hypotension, especially during initial therapy. Dental professionals should be informed of Hypernil use due to potential gingival hyperplasia association. Patients with heart failure should be monitored closely, as calcium channel blockers may exacerbate symptoms in some cases.
Contraindications
Hypernil is contraindicated in patients with known hypersensitivity to amlodipine or any component of the formulation. It must not be administered to patients experiencing cardiogenic shock or clinically significant hypotension (systolic pressure <90 mmHg). The medication is contraindicated in patients with unstable angina not adequately controlled by beta-blockers or other antianginal therapies. Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin requires careful risk-benefit assessment due to significantly increased amlodipine exposure. Patients with severe hepatic impairment (Child-Pugh Class C) should not initiate therapy without specialist consultation.
Possible side effect
The most frequently reported adverse reactions include peripheral edema (dose-dependent, occurring in 5-15% of patients), headache (7-10%), dizziness (3-5%), and flushing (4-7%). Less common effects include palpitations (1-3%), nausea (2-4%), abdominal pain (1-2%), and somnolence (1-2%). Rare but clinically significant side effects may include hypotension (<1%), syncope (<0.5%), and allergic reactions including angioedema (<0.1%). Some patients may experience gingival hyperplasia, particularly those with poor oral hygiene. Laboratory abnormalities are infrequent but may include transient elevations in liver enzymes. Most adverse effects are mild to moderate in severity and often diminish with continued therapy.
Drug interaction
Hypernil demonstrates several clinically relevant interactions requiring careful management. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may increase amlodipine concentrations by up to 80%, necessitating dosage reduction. Concomitant use with other antihypertensive agents may produce additive blood pressure-lowering effects. Simvastatin coadministration may increase simvastatin exposure by approximately 25%. Cyclosporine administration may increase amlodipine concentrations while amlodipine may increase cyclosporine levels, requiring close monitoring. Sildenafil and other phosphodiesterase-5 inhibitors may potentiate hypotensive effects. Grapefruit juice may increase bioavailability and should be avoided. Non-steroidal anti-inflammatory drugs may reduce the antihypertensive efficacy.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If the next scheduled dose is due within 12 hours, the missed dose should be skipped. Patients should never double the dose to make up for a missed administration. Consistent once-daily timing is important for maintaining stable blood pressure control. Those who frequently forget doses should consider implementing reminder systems or discussing alternative treatment schedules with their healthcare provider. Abrupt discontinuation is not associated with rebound hypertension, though blood pressure may gradually return to pretreatment levels.
Overdose
Amlodipine overdose may manifest as profound hypotension and reflex tachycardia. Cases of significant overdose may progress to shock with metabolic acidosis and pulmonary edema. Management involves cardiovascular monitoring with intensive supportive care. Gastric lavage may be considered if presentation occurs within 1-2 hours of ingestion. Activated charcoal administration may be beneficial. Intravenous calcium gluconate (10% solution) has been used with variable success to reverse calcium channel blockade. Vasopressor agents such as dopamine or norepinephrine may be required for blood pressure support. Bradycardia may respond to atropine administration. Due to the long half-life, monitoring should continue for at least 24-48 hours. Dialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use if the blister pack is damaged or tablets show signs of discoloration or degradation. Properly dispose of expired or unused medication through drug take-back programs or according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Hypernil is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary based on numerous factors including age, renal function, hepatic function, and concomitant medications. Patients should not initiate, adjust, or discontinue Hypernil without consulting their physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Healthcare providers should reference the complete prescribing information before making treatment decisions.
Reviews
Clinical studies demonstrate Hypernil’s efficacy with 75-85% of hypertensive patients achieving target blood pressure goals (<140/90 mmHg) at 10 mg daily dosage. In the VALUE trial subset analysis, amlodipine-based regimens showed superior systolic blood pressure reduction compared to other antihypertensive classes. Long-term extension studies indicate maintained efficacy over 52 weeks with consistent safety profile. Real-world evidence from prescription databases indicates high patient persistence rates at 12 months (68%) compared to other antihypertensive classes. Cardiology guidelines consistently position calcium channel blockers like Hypernil as first-line options, particularly for elderly patients and those of African descent. Patient-reported outcomes indicate high satisfaction with once-daily dosing and minimal interference with daily activities.